Txn1 F54L Mutant Rat Model for Oxidative Stress Disease Research
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of non-human animal models that effectively replicate diseases caused by diminished thioredoxin function, which are relevant for studying aging, kidney disease, cardiovascular disease, hypertension, aortic dissection, chronic obstructive pulmonary disease, age-dependent epilepsy, dyslipidemia, anemia, osteoporosis, and immune disorders.
Innovation Solution
A non-human animal model is developed by modifying the Txn1 gene in rats to introduce mutations that reduce thioredoxin function, allowing for the creation of homozygous and heterozygous models that exhibit these diseases, enabling their use as research models for disease pathology and therapeutic agent screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a thioredoxin-deficient mouse is created using conventional techniques, then the model can study oxidative stress-related diseases, but the homozygous mouse dies in the fetal period and cannot be used for disease modeling
Solution Approach 1:
The invention changes the genetic parameter from complete deficiency (null mutation) to partial deficiency (F54L point mutation). This parameter change allows the animal to remain viable while still exhibiting reduced thioredoxin function, thereby resolving the contradiction between model reliability and productivity.
2Reliability
If the Txn1 gene is completely knocked out to create a thioredoxin-deficient model, then oxidative stress protection is eliminated, but the animal cannot survive to study adult diseases
Solution Approach 1:
Instead of complete gene knockout, the invention applies partial action by introducing a point mutation (F54L) that reduces but does not eliminate thioredoxin function. This partial deficiency is sufficient to create oxidative stress vulnerability while maintaining animal survival, allowing study of adult diseases.
3Adaptability or versatility
If a transgenic animal expressing dominant negative thioredoxin is created, then hypertrophic cardiomyopathy can be modeled, but the model is limited to specific disease types and tissues
Solution Approach 1:
The invention creates a universal model by using a point mutation in the endogenous Txn1 gene that affects thioredoxin function systemically throughout the organism. This single genetic modification can model multiple different oxidative stress-related diseases across various tissues and age groups, rather than being limited to one specific disease type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified thioredoxin gene models in rats demonstrate reduced thioredoxin activity, leading to the development of diseases such as aging, kidney disease, cardiovascular disease, and immune disorders, providing a valuable tool for elucidating disease mechanisms and screening therapeutic agents.
Implementation Method 1
The dithiol/disulfide exchange reaction between the cysteine residues contributes to the redox reaction of the substrate. The reduced thioredoxin bearing dithiol reduces the disulfide bond of a substrate protein and becomes itself in oxidized form.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided is a nonhuman animal model that is obtained by modifying a gene encoding thioredoxin and useful as a disease model of aging, kidney diseases, cardiovascular diseases, hypertension, aortic dissection, chronic obstructive lung disease, age-dependent epilepsy, abnormality of lipid metabolism, anemia, osteoporosis, abnormal immunity, etc. These variety of phenotypes are caused by the fact that a modification of a gene encoding thioredoxin induces hypofunction of thioredoxin expressed in multiple organs throughout the body. The gene encoding thioredoxin is a gene selected from among TXN, TRX, TRX1, RRDX, Txn1, Txn, Trx1 and ADF.